Medical Devices - SERBIA

Competent authority

Contact Details	**Contact Name 1** Medicines and Medical Devices Agency of Serbia/ Agencija za lekove i medicinska sredstva Srbije (ALIMS) **Phone** +381 11 3951-158; +381 11 3951-199 **Fax** +381 11 3951-158 **Email Department** hygia@alims.gov.rs **Address** 458, Vojvode Stepe Street **ZIP/City** 11221 Belgrade **Country** Serbia (RS) **Web address** http://www.alims.gov.rs/eng/medical-devices/
Trial Authorisation / Registration / Notification	**Regulatory and ethics bodies involved in approval process** Competent Authority/-ies (CA) Ethics committee(s) **CA - Submission for authorisation mandatory for** MD Class IIa MD Class IIb MD Class III **CA - Registration/ notification without approval required for** – **CA - Submission required to** National CA **National trial registry** ALIMS has an official national register. **Applicable national legal framework/ Reference** Art 47 of Rulebook Application 2011 **Submission to CA and EC to be performed in the following order** –
Submission of Application	**Responsible for study submission** Sponsor

	Entitled to study submission – **Prerequisites for submission** Positive opinion by relevant EC(s) **Guidance on submission of application** A comprehensive official guidance, based on Law on MP & MD 2010, is available in English on the ALIMS Website in Section: Regulations » Rules for Medical Devices: 'Rulebook on the Contents of the Application, and/or Documentation on the Approval of Clinical Trials for Medicines and Medical Devices, as well as the Method of Implementation for Clinical Trials of Medicines and Medical Devices' **Applicable national legal framework/ Reference** Art 26 & 47-48 Rulebook Application 2011
Submission Format	**Format option(s)** Paper form (or electronically + in writing); in the script in official use in the RS. **Preferred format** – **Standard application form available** Yes **Standard application form** The standard application form (Form 1) to be used for notification/ request for authorization is available (in Serbian and cyrillic script only) on the ALIMS website in section Regulativa » Medicinska sredstva» Obrasci (Obrazac za odobrenje / prijavu kliničkog ispitivanja medicinskog sredstva). **Guidance on submission format** Art 7 of the Rulebook Application 2011 **Applicable national legal framework/ Reference** Art 7 of the Rulebook Application 2011
Language of Submission	**Language(s) of application** Serbian English **Preferred language of application** – **English accepted** e.g. Protocol, CRF Investigator’s Brochure, etc. **Documents mandatory to be in official national language** Protocol Summary Information material, Documents and Forms intended for study participants and patient information **Documents mandatory to be in local language of study site** – **Documents mandatory to be in language of the study participant** –

	Applicable national legal framework/ Reference Art 6 of the Rulebook Application 2011
Submission Fees	**Fees for trial submission mandatory** Yes **Fees** Clinical investigations of medical devices: 22800 RSD (approx. 190€) Clinical investigations of registered medical device: 6000 RSD (approx 50€) Amendments: 12000 (approx. 100€) **Waiver for academic (non-commercial) studies possible** Not specified **Official guidance on required fees** Pricelist is provided on ALIMS website (in serbian and cyrillic script only).
Timelines Authorisation	**General timespan (max nr days)** 60 **Mode of approval (General)** – **Clock-stop possible if complementary information requested** Yes **Timespan counted from** Date of submission of valid application **Applicable national legal framework/ Reference** Art 80-82 Law on MP & MD 2010 **Additional Information** In case of incompleteness of the application, the sponsor has 30 days to submit the missing information/documentation. Submission to the national CA is anytime possible. NB! There is no parallel application process to CA and EC(s) in Serbia. A positive vote of the EC is a prerequisite for CA application and approval.
Amendments/ Substantial Amendments (SA)	**Notification mandatory for** – **Authorisation mandatory for** Any substantial amendments **Responsible for submission of SA** – **Timeline for approval of SA (max nr days)** 30 From date of submission One clock stop possible if complementary information requested Positive EC vote is prerequisite for CA approval **Guidance on submission of SA** Details on types and definitions of substantial amendments as well as on the application procedure, along with the required documentation, are provided in Art 13-22 of the Rulebook Application 2011.

Applicable national legal framework/ Reference

Art 85 Law on MP & MD 2010
Art 13-23 Rulebook Application 2011

Additional Information

Procedure: Local EC approval must be obtained prior to CA submission and approval.
NB! No prior EC opinion is required, if the substantial amendment is related to the quality of the investigational medicine and/or changes to the bearer of the authorization for the implementation of clinical trials for the medicine. (pursuant to Art 22 Rulebook Application 2011).

Safety Reporting

Responsible for AE reporting to CA

Sponsor

Sponsor must declare reportable events to

Competent Authority
Relevant EC(s)
All investigators

Reportable AEs

SAE (Serious Adverse Event)
ADE (Adverse Device Effect)
SADE (Serious Adverse Device Effect)

SUSAR being life-thereatening or leading to death must be reported

–

All other SUSARs

–

SAE /SADE must be reported

Immediately
(Reportable events must be fully recorded)

National standard reporting form available

Yes

Standard Reporting Form

Standard AE reporting form is available (in Serbian and cyrillic script) on the ALIMS website in section Regulativa » Medicinska sredstva» Obrasci (“Obrasci za prijavljivanje neželjenih reakcija na medicinsko sredstvo”)

Reporting format - Options

–

Preferred format

–

Provision of Annual safety report mandatory

Yes

Annual safety report shall be provided by sponsor to

National CA

Guidance on AE reporting procedure

An Annual safety report on all adverse reactions must be submitted by the sponsor to the national CA. Attachment 6 of the Rulebook Rulebook AR reporting 2011 prescribes in detail the required contents of the safety report.

Applicable national legal framework/ Reference

Art 92 Law on MP & MD 2010
Rulebook AR reporting 2011

Additional Information

Sponsor is required to report quarterly to the national CA and the EC about the conduct of the clinical trial, pursuant to Art 92 Law on MP & MD 2010. The tri-monthly report encompasses the number of subjects involved per site, the occurrence of adverse reactions as well as other relevant data related to the implementation of the clinical trial.

Investigator shall report SAE to

–

Reporting timeline

–

End of Trial

End of trial declaration mandatory for

All clinical investigations requiring authorisation by CA

Responsible for End of trial declaration

Sponsor

Regular Termination - Declaration timespan (max nr days)

90

Timespan counted from

–

Early/premature Termination - Declaration timespan (max nr days)

15

Standard Declaration form

The standard End of trial declaration form (Form 3) to be used is available (in Serbian and Cyrillic script only) on the ALIMS website in section Regulativa » Humani Lekovi » Obrasci (Obrasci vezani za klinička ispitivanja lekova » Obaveštenje o završetku kliničkog ispitivanja).

Applicable national legal framework/ Reference

Art 92 Law on MP & MD 2010

Additional Information

Final report shall be submitted to the Agency within one year.

Ethics committee

Contact Details

Contact Name 1

There are approximately 30 local ECs in Serbia:

Contact Name 2

Hospitals, health care institutions, clinical centres and the Serbian Medical Society have their own EC for review of CT applications

Contact Name 3

(1) Serbian Medical Society- Ethics Committee

Address

Dzordza Vasingtona 19

	ZIP/City 11000 Belgrade **Country** Serbia (RS) **E-Mail** sld@bvcom.net **Web address** http://www.sld.org.rs **Additional Information** (2) Clinical Centres (with websites) are: • Clinical Centre Serbia: www.klinicki-centar.rs • Clinical centre Vojvodina www.kcv.rs • Clinical centre Kragujevac www.kc-kg.co.rs • Clinical Centre Nis • Clinical-Hospital Centre Zemun • Clinica-Hospital Centre Zvezdara • Clinical-Hospital Centre Bezanijska kosa There is no central EC. For ECRIN CEC is ECSMS.
Ethical Review – General	**Submission for Ethical review mandatory for** All clinical investigations of MD **Submission to CA and EC to be performed in the following order** EC first Positive EC opinion required for CA application/approval **Regulatory and ethics bodies involved in approval process** –
Single-Centre Studies - Ethical Review	**Ethical approval (favourable opinion) to be obtained from** Local EC **Additional Information** The local EC of the respective trial site reviews the CT application and issues a reasonable opinion. There are approximately 30 local ECs in Serbia (Hospitals, health care institutions, clinical centers, Serbian Medical Society).
Multi-Centre Studies - Ethical Review	**Ethical approval (favourable opinion) required from** All local ECs of participating sites **Submission of application required to** –

	Additional Information There is no central EC for the evaluation of multi-centre trials (MCT). MCT must be submitted for approval to the local ECs of the trial sites where the clinical trials are being performed. The Local ECs assess the clinical trial and issue their opinion on the applications independently. There is no single opinion procedure! (Art 42 Rulebook Application 2011). Multi-centre clinical trials are conducted in accordance with the provisions pursuant to Art 93 of the Law on MP & MD 2010 . For ECRIN research: Lead EC will be Serbian Medical Society Ethic Committee (SMS EC), for application submission. The final decision will be given from SMS EC after local EC approval.
Submission of Application	**Responsible for study submission** Sponsor Principal Investigator **Entitled to study submission** – **Prerequisites for submission / approval** –
Submission Format	**Format option(s)** Paper form or electronic format (depending on the specifications of the EC concerned) **Preferred format** –
Language of Submission	**Language(s) of application** Serbian English **Preferred language of application** – **English accepted** Partly, not for all documents **Documents mandatory to be in official national language** Information material, Documents and Forms intended for study participants and patient information **Documents mandatory to be in local language of study site** – **Documents mandatory to be in language of study participant** –
Submission Fees	**Fees for Ethical review** Evaluation fees charged from the sponsor depend on the EC concerned, e.g.: EC Clinical Centre of Serbia: € 1200.- (for commercial studies) EC Clinical centre of Kragujevac: € 1200.- EC Clinical Centre of Vojvodina: € 800.- For ECRIN research: Applications to SMS (Serbian Medical Society) are free of charge
Timelines Ethical Review	**General timespan for single-centre studies (max nr days)** 30

	General timespan for multi-centre studies (max nr days) 30 **External expert advice required: Timespan (max nr days)** – **Timespan counted from** – **Additional Information** Submission to EC is possible anytimes, no deadlines apply . NB! it is NOT possible to request the 2 authorisation in parallel. EC opinion must be obtained prior to CA submission/ approval.
Amendments/ Substantial Amendments (SA)	**Ethical review mandatory for** Any substantial amendments (except related to quality of investigational medicine) **Responsible for notification of SA** Sponsor **Timeline Ethical review of SA (max nr days)** – **Applicable national legal framework/ Reference** 20-22 Rulebook Application 2011 **Additional Information** NB! Assessment by the EC(s) is not required if the substantial amendments are related to the quality of the IMP and/or changes to the bearer of the authorization for the implementation of clinical trials for the medicine (Art 20-22 Rulebook Application 2011)
Safety Reporting	**Adverse Events (AE) - Definitions (pursuant to national law)** Defintions of AE are provided in the Rulebook of AR reporting 2011. **Reportable AEs** – **Investigator shall report SAE to** – **Reporting timeline** – **Responsible for AE reporting to relevant EC(s)** – **SUSAR being life-thereatening or leading to death must be reported** – **All other SUSAR must be reported** – **SAE/SADE must be reported** – **National Standard Reporting form available** –

	Reporting format - Options – **Preferred reporting format** –
End of Trial	**End of trial Declaration mandatory** Yes **Responsible for End of trial Declaration** Sponsor **Regular Termination - Declaration timespan (max nr days)** 90 **Timespan counted from** – **Early/premature Termination - Declaration timespan (max nr days)** 15 **Applicable national legal framework/ Reference** Art 92 Law on MP & MD 2010

Study specific Requirements

Sponsor	**Sponsor - Definition available in national law** Yes **Sponsor - Definition (pursuant to national law)** Clinical trial sponsor is an individual or a legal entity that takes responsibility for commencing, conducting, and/or financing a clinical trial (Art 2 Law on MP & MD 2010) Clinical trial sponsor can be a manufacturer, legal or physical entity, who is responsible for the initiation, management, quality and financing of the clinical trial conduct. (Art 71 Law on MP & MD 2010) **Sponsorship mandatory** Yes **Sponsorship mandatory - Additional information** Mandatory in all investigations of Medical Devices. **Co-Sponsor - Definition available in national law** No **Co-sponsorship allowed** No
Investigator	**Entitled to be principal investigator** – **Additional Information** Training/ Qualification of Prinicipal Investigator: Qualification of the investigator shall be according to Art 30 of Rulebook Application 2011 GCP training for investigators is required (Section for Clinical pharmacology of Serbian Medical Society accredited in Serbian Medical Chamber Continious Medical Education: Good Clinical Practice in clinical investigation)

Study Participants - Informed Consent (IC)	**IC is regulated by law** Yes **Informed Consent - Definition/ Requirements** The definition for “Informed subject consent” resp. “willing informed consent” is provided in Art 2 (9) of Rulebook Application 2011. Informed consent must be obtained from the study participants in written form (in verbal form under special provisions) and in Serbian language according Art 61 of Rulebook Application 2011. **Additional Information** There are specific requirements to be considered for vulnerable populations such as children, pregnant and lactating women, prisoners and adults who are not able to give written consent for trial participation (according to Art 63-67 of Rulebook Application 2011).
Study Participants - Vulnerable Population	**Minors / Children - Studies allowed** Yes Special provisions apply **Legal framework/Reference (Minors/Children)** Art 63-65 Law on MP & MD 2010 **Incapacitated persons - Studies allowed** Yes Special provisions apply **Legal framework / Reference (Incapacitated persons)** Art 66 Law on MP & MD 2010 **Emergency situations - Studies allowed** Yes Special provisions apply **Emergency situation without prior consent of patient or proxy - Studies allowed** No **Legal framework / Reference (Emergency Situation)** Art 66 Law on MP & MD 2010 **Pregnant or breastfeeding women - Studies allowed** Yes With limitations Special provisions apply **Specific provisions** Clinical trials on healthy pregnant or lactating women are prohibited. **Legal framework / Reference (Pregnant or breastfeeding women)** Art 63 Law on MP & MD 2010

National legal framework for protection of vulnerable populations in place

Yes

Applicable legal framework / Reference (Vulnerable Population)

Art 63-67 of Rulebook Application 2011

Study Participants - Recruitment & Trial Outcome

Additional Information

Investigators can publish results of academic studies. For sponsored studies it is mandatory to have sponsor permission (in accordance with GCP, EU Directive 2001, and good scientific practice).

Data Protection

Notification to DP Authority/ Ombudsmann is mandatory

No

Approval/ authorisation required

No

Specific notification timelines before operations start

–

Language of notification

–

Notification format

–

Data Protection Authority/ Agency - Contact Details

Commissioner for Information of Public Importance and Personal Data Protection/ Poverenik za informacije od javnog značaja i zaštitu podataka o ličnosti (sr)

Phone

+381 11 3408 900

Fax

+381 11 3343 379

E-Mail

office@poverenik.rs

Web address

http://www.poverenik.rs/en.html

Address

15, Bulevar kralja Aleksandra str

ZIP/City

11000 Belgrade

Country

Serbia (RS)

Additional Information

The Serbian Law on Personal Data Protection (Official Gazette of the RoS, no. 97/2008 and 104/2009) regulates the collection, processing and use of personal data such as patient data etc.

Inadequate data processing and non-compliance with the Law results in liability for an offence and the prescribed sanction is a monetary fine in the amount of up to RSD 1,000,000.00 (approximately EUR 10,824.00).
In addition, unauthorized collecting of personal data is prescribed as a criminal offence by the Criminal Code of the Republic of Serbia. It is stipulated that the person who collects, announces to others or uses for the purpose for which personal data are not intended to be used, shall be punished with a monetary fine or a prison for up to a year, i.e. up to three years if stated actions are undertaken by an official in performing its duties.

Legal framework (on safeguarding the collection, handling, recording, keeping and/or processing of any clinical trial related data and patient files)

–

Insurance

Liability insurance or alternative arrangements for damages mandatory for

Study participants

Responsible for covering insurance

Sponsor

Insurance fee: A minimum coverage sum is defined

No

Applicable national legal framework/ Reference

Art 72 Law on MP & MD 2010
Art 6 (18) of Rulebook Application 2011

Additional Information

Prior to the commencement of a clinical trial, the sponsor is obliged to contract insurance in the event of health damage caused by the clinical trial. Insurance is mandatory in all interventional investigations on MD and registries.

Quality Assurance/ Quality Control (QA/QC)

Monitoring

Compulsory

Audit by sponsor

Compulsory

Standard Operating Procedures (SOPs)

Compulsory

Archiving & Data Management

Study documents must be kept at least (in years)

5

National legislation

General Information: Applicable Legislation & Conventions

Official website providing relevant national legislation available

Yes

	Official website providing relevant national legislation Website of the National CA (ALIMS) provides the national legislation in Serbian and English.
Investigations on Medical Devices	**Applicable national regulations** – **Act on Medical Devices (or comparable national legal framework)** Law on Medicines and Medical Devices/ Zakon o lekovima i medicinskim sredstvima (“Sl. glasnik RS” br. 30/2010 i 107/2012), published in the “Official Gazette of the Republic of Serbia” No. 30/2010 dated 7th May 2010; hereinafter referred to as Law on MP & MD 2010 This law determines the performance of the national CA (ALIMS) in Serbia and all significant issues related to medicinal products and medical devices, such as clinical trials, marketing authorization procedure, etc. Pursuant to Art 199 of this law, clinical investigations on Medical Devices are to be performed in accordance with the provisions of the current Law on conducting clinical trials with Medicinal Products. **Other applicable regulations / implementing provisions (Acts, laws, decrees, ordinances, circulars, etc)** Pursuant to Art 78 (par 3), Art 199 (par 3) and Art 161 (par 8) of Law on MP & MD 2010, the Minister of Health implemented this law by adopting the following regulations: (1) Rulebook on the Contents of the Application, and/or Documentation on the Approval of Clinical Trials for Medicines and Medical Devices, as well as the Method of Implementation for Clinical Trials of Medicines and Medical Devices (hereinafter referred to as “Rulebook Application 2011”) (Published in the „Official Gazette of the RS”, nr. 64/2011 of 31 August 2011) It prescribes the content, and/or documentation for the approval of clinical trials for medicines and medical devices, as well as the method of implementation for clinical trials of medicines and medical devices in human medicine. (2) Rulebook on the method of reporting, collecting and monitoring adverse reactions to medicines (hereinafter referred to as “Rulebook AR reporting 2011”) The Rulebook was published in the “Official Gazette of RS”, No. 64/2011 of 31 August 2011
Radiation & Radiotherapy	**Use of radiation or radioactive compounds - Specific requirements** Yes **Applicable legal framework** It is defined as medical device class III and it is regulated by the Serbian Law on MP & MD 2010. For authorization, additional requirements for medicines with specific characteristics such as radiopharmaceuticals must be met (Art 6 the Rulebook Application 2011).
Data Protection	**Legal framework (on safeguarding the collection, handling, recording, keeping and/or processing of any clinical trial related data and patient files)** National Data Protection Act **National DP act** The Serbian Law on Personal Data Protection (Official Gazette of the RoS, no. 97/2008 and 104/2009) regulates the collection, processing and use of personal data such as patient data etc.

Definition

MD/MD Investigation	**MD - Definition available in national law** Yes **MD - Definition** Definitions for the various types and classifications of Medical Devices are available in Art 171-176 Law on MP & MD 2010 as well as on the ALIMS website in section Medical Devices. **Investigation of MD - Definition available in national law** Yes **Investigation of MD - Definition** Clinical trial of Medical Devices (pursuant to Art 2(63) Law on MP & MD 2010): 'the process of establishing or confirming that its security and efficiency are in line with the declared application defined by the manufacturer'